Filtered By:
Specialty: Nanotechnology
Cancer: HER2
This page shows you your search results in order of date.
Order by Relevance | Date
Total 8 results found since Jan 2013.
Inhibiting HER3 Hyperphosphorylation in HER2 ‐Overexpressing Breast Cancer through Multimodal Therapy with Branched Gold Nanoshells
A multimodal theranostic nanoplatform to treat breast cancer overexpressing the human epidermal growth factor receptors 2 (HER2) and 3 (HER3) is developed, and consisting of doxorubicin-loaded branched gold nanoshells functionalized with a small interfering RNA against HER3 and the HER2-specific antibody Trastuzumab able to simultaneously combine chemo- and photothermal, RNA silencing and immuno-therapies overcoming chemoresistance and reducing tumor size in vivo. AbstractTreatment failure in breast cancers overexpressing human epidermal growth factor receptor 2 (HER2) is associated mainly to the upregulation of human epid...
Source: Small - August 26, 2023 Category: Nanotechnology Authors: Eva Villar ‐Alvarez,
Irene Golán‐Cancela,
Alberto Pardo,
Brenda Velasco,
Javier Fernández‐Vega,
Adriana Cambón,
Abeer Al‐Modlej,
Antonio Topete,
Silvia Barbosa,
José A. Costoya,
Pablo Taboada Tags: Research Article Source Type: research
Precision Therapy of Recurrent Breast Cancer through Targeting Different Malignant Tumor Cells with a HER2/CD44‐Targeted Hydrogel Nanobot
Schematic illustration of the preparation of a HER2/CD44-targeted hydrogel nanobot (ALPR) by embedding the positively charged bio-responsive, liposome-encapsulated nanoparticles (LPR) formed by cationic liposome DOTAP/DOPE, survivin siRNA, andD-(KLAKLAK)2GGR16 (KLA-R16) into negatively charged Herceptin/hyaluronic acid cross-linked nanohydrogels (Herceptin-HA). AbstractHeterogeneity and drug resistance of tumor cells are the leading causes of incurability and poor survival for patients with recurrent breast cancer. In order to accurately deliver the biological anticancer drugs to different subtypes of malignant tumor cells...
Source: Small - May 8, 2023 Category: Nanotechnology Authors: Juan Chen,
Jinjin Li,
Xiaolu Sun,
Huixia Lu,
Kuai Liu,
Zhenbo Li,
Jianyue Guan,
Huiling Song,
Wei Wei,
Yanhong Ge,
Qiong Fan,
Wei Bao,
Buyong Ma,
Zixiu Du Tags: Research Article Source Type: research
Targeted Nanoparticle for Co ‐delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis (Small 11/2022)
Breast Cancer TreatmentIn article number2107550, Wassana Yantasee and co-workers develop polymer-decorated mesoporous silica nanoparticles for HER2-positive breast cancer treatment. This patented versatile platform can co-deliver multiple therapeutic classes to ensure that they reach the target cells at the same time to fully realize their synergy. Illustrated herein are nanoparticles with three drug cargos: HER2 antibody, HER2 siRNA, and chemotherapeutic docetaxel.
Source: Small - March 17, 2022 Category: Nanotechnology Authors: Worapol Ngamcherdtrakul,
Daniel S. Bejan,
William Cruz ‐Muñoz,
Moataz Reda,
Husam Y. Zaidan,
Natnaree Siriwon,
Suphalak Marshall,
Ruijie Wang,
Molly A. Nelson,
Justin P. C. Rehwaldt,
Joe W. Gray,
Kullervo Hynynen,
Wassana Yantasee Tags: Cover Picture Source Type: research
Targeted Nanoparticle for Co ‐delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis
This research paper describes a new therapeutic candidate based on a nanoparticle that co-delivers siRNA against human epidermal growth factor receptor type 2 (HER2), trastuzumab, and docetaxel to treat advanced HER2+ breast cancer. The nanotherapeutic is more effective and safer than the free drug counterparts. It inhibits drug-resistant orthotopic and brain-metastatic HER2+ breast tumors in mice. AbstractThe first-line treatment of advanced and metastatic human epidermal growth factor receptor type 2 (HER2+) breast cancer requires two HER2-targeting antibodies (trastuzumab and pertuzumab) and a taxane (docetaxel or pacli...
Source: Small - January 27, 2022 Category: Nanotechnology Authors: Worapol Ngamcherdtrakul,
Daniel S. Bejan,
William Cruz ‐Muñoz,
Moataz Reda,
Husam Y. Zaidan,
Natnaree Siriwon,
Suphalak Marshall,
Ruijie Wang,
Molly A. Nelson,
Justin P. C. Rehwaldt,
Joe W. Gray,
Kullervo Hynynen,
Wassana Yantasee Tags: Research Article Source Type: research
A display of pH-sensitive fusogenic GALA peptide facilitates endosomal escape from a Bio-nanocapsule via an endocytic uptake pathway
Conclusion:
The genetic fusion of a GALA peptide to the virus-like particle confers the ability of endosomal escape.
Source: Journal of Nanobiotechnology - April 1, 2014 Category: Nanotechnology Authors: Yuya NishimuraKoichi TakedaRyosuke EzawaJun IshiiChiaki OginoAkihiko Kondo Source Type: research
Targeting cancer cell-specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes
Conclusions:
These findings show that, in the field of nucleic acid medicine, ZHER2-BNC/LP can be a useful carrier for siRNA delivery, and could also become a useful tool for gene silencing and to accomplish protein knock-down.
Source: Journal of Nanobiotechnology - June 24, 2013 Category: Nanotechnology Authors: Yuya NishimuraHiroaki MiedaJun IshiiChiaki OginoToshinobu FujiwaraAkihiko Kondo Source Type: research
